vasoconstriction

Clazosentan (Ro 61-1790) 是一种特异性内皮素 A (ETA）受体拮抗剂,抑制 ET-1 介导的血管痉挛。Clazosentan 可用于研究神经系统疾病和心血管疾病。

Perindopril erbumine (S9490-3) 是一种长效血管紧张素转换酶抑制剂。

Uridine-5'-diphosphate disodium salt (UDP disodium salt) 是一种选择性 P2Y6受体激动剂，EC50为300 nM，对人 P2Y6受体的 pEC50为6.52。它可刺激炎症介质的产生、吞噬作用和血管收缩，催化多种底物的葡糖醛酸糖化反应，用于核酸生物合成。

Ketanserin (Ketanserinum) 是一种喹唑啉衍生物和 5-羟色胺受体亚型 2 拮抗剂，具有潜在的抗高血压和抗血小板活性。它也浓度依赖性抑制 hERG 电流，IC50为 0.11 μM。

Tolazoline (Benzalolin) 是一种竞争性的α-肾上腺素受体拮抗剂。

Phenoxybenzamine hydrochloride (NCI-c01661) 是一种选择性的 α-adrenoceptor 和 calmodulin 的抑制剂，是常用的抗高血压药。

Candesartan Cilexetil (TCV-116) 是一种血管紧张素II 拮抗剂，可用于治疗高血压。

Danshensu sodium salt (Sodium Danshensu) 是从中国草本丹参中提取的一种天然产物，可以抑制去氧肾上腺素和CaCl2 在无Ca2+ 培养基中引起的血管收缩。

Naphazoline hydrochloride (Naphazoline HCl) 是一种咪唑啉衍生物，是一种眼血管收缩剂。

Neocuproine 是一种铜 （I） 螯合剂，可增强电场刺激引起的输精管收缩的嘌呤能成分，常被用作配位试剂和铜离子检测剂。Neocuproine 与铜离子形成稳定的络合物，并可在某些化学反应和分析方法中起到催化作用。Neocuproine 作为铁和钴上的氧化还原活性配体平台，对NSC34细胞氧化损伤的保护作用。

Angiotensin amide acetate 是Angiotensin amide 的衍生物。Angiotensin amide 是一种八肽酰胺，可以通过血管收缩来提高血压。

Naphazoline (Naphcon-a) 是一种具有显着 α 肾上腺素能活性的拟交感神经化合物。 萘甲唑啉可用作血管收缩剂，当应用于粘膜时可快速减少肿胀。

Naratriptan hydrochloride (GR-85548A hydrochloride) 是一种5-HT1受体激动剂，有抗偏头疼特性。它还可以通过刺激三叉神经系统感觉神经末梢上的 5-HT1D 1B 受体来发挥其作用，从而减少促炎神经肽的释放。

Methoxamine hydrochloride (Methoxamine HCl) 是一种 alpha1 肾上腺素能受体的选择性激动剂。它通过 Prazosin 敏感机制在兔肺动脉显著增加 ATP、ADP 和 AMP 的溢出，但不增加腺苷的溢出。它引起血管收缩和外周血管阻力增加。

Benzamil 是 Amiloride 类似物，是 Na+ Ca2+交换体抑制剂，抑制 TRPP3 介导的 Ca2+激活电流，IC50为 1.1 μM。它也是一种非选择性上皮钠通道 (ENaC) 阻滞剂，能增强肌源性血管收缩。

Angiotensin I (human, mouse, rat) 是血管紧张素Ⅱ的前体物质，在血管紧张素转化酶 (ACE) 的参与下裂解成血管紧张素Ⅱ。

TRV-120027 TFA 是一种血管紧张素 II 介导的血管收缩抑制剂，可增加心肌细胞的收缩力。它是一种偏向 β-arrestin-1 的 AT1R 激动剂，可与 ß-arrestins 结合，同时阻断 G 蛋白信号传导。 它通过阳离子通道亚家族 C3 (TRPC3) 偶联诱导急性儿茶酚胺分泌，并促进在质膜上形成由 AT1R-β-arrestin-1-TRPC3-PLCγ 组成的大分子复合物。

Almotriptan (LAS 31416) 是一种用于研究偏头痛的5-HT1B 1D 受体激动剂。

Ketanserin tartrate (KJK-945 tartrate) 是 5-HT2A 受体和α1-肾上腺素能受体拮抗剂，具有抗高血压活性，抑制血清素诱导的血管收缩和血小板活化，可用于研究系统性硬化症。

Terlipressin Acetate 是一种高度选择性的加压素 V1 受体激动剂，对氧和葡萄糖剥夺 再氧合 (OGD R) 诱导的肠上皮细胞损伤 (IEC-6) 具有抗炎和抗氧化作用，可用于肝肾综合征和耐去甲肾上腺素的败血性休克的研究。

Nadolol 是一种有机阴离子转运多肽 1A2 (OATP1A2) 的底物，是一种非选择性的、具有口服活性的 β-肾上腺素受体 (β-adrenergic receptors) 阻滞剂，可用于高血压，心绞痛和血管性头痛的研究。

Aprikalim (RP 52891) 是一种三磷酸腺苷钾通道（KATP）开启剂，可保护脊髓缺血兔模型中的神经受到损伤。Aprikalim 抑制血管收缩，抑制心肌麻痹期间 [Ca2+]i 升高，可以用于研究心血管疾病。

(±)18-HETE is the racemic version of a cytochrome P450 (CYP450) metabolite of arachidonic acid. When formed by the CYP2E1 isoform, 18-HETE is comprised 100% of the (R) isomer. 18(R)-HETE dose-dependently stimulates vasodilation of the rabbit kidney, whereas 18(S)-HETE does not affect perfusion pressure. 18-HETE has negligible effects on ATPase activity. 18(R)-HETE at 1 μM completely blocks 20-HETE-induced vasoconstriction of renal arterioles.

Forasartan is a non - peptide angiotensin II receptor antagonist with antihypertensive activity. Forasartan and angiotensin II compete to bind AT1 receptor subtypes in vascular smooth muscle, thereby blocking angiotensin II-mediated vasoconstriction, lead

5(6)-EET is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5(6)-EET degrades into 5,6-DiHET and 5(6)-δ-lactone, which can be converted to 5(6)-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5(6)-EET has been implicated in the mobilization of calcium and hormone secretion. 5(6)-EET is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC50 = 0.54 μM), and Cav3.3 and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2, as measured by oxygen consumption and product formation assays when used at a concentration of 50 μM. (±)5(6)-EET is provided as a mixture of the free acid and lactone.

Angiotensin amide, an octapeptide amide, can be used to increase blood pressure by vasoconstriction.

Nadolol-d9 (Mixture of Diastereomers) 是 Nadolol 的氘代化合物。Nadolol 的 CAS 号为 42200-33-9。Nadolol 是一种有机阴离子转运多肽 1A2 (OATP1A2) 的底物，是一种非选择性的、具有口服活性的 β-肾上腺素受体 (β-adrenergic receptors) 阻滞剂，可用于高血压，心绞痛和血管性头痛的研究。

神经肽Y（Neuropeptide Y, NPY）是一种参与调节食欲、血管收缩、心脏收缩力和肠道分泌的神经肽，同时也是NPY受体Y1、Y2和Y5的激动剂。它在全身范围内表达。NPY能够在表达大鼠Y1或Y2以及表达大鼠Y5的HEK293细胞中选择性抑制由forskolin诱导的cAMP积累，而对表达大鼠Y4受体的L-M(TK-)细胞的影响较小（EC50分别为0.15、2.7、0.66和>1,000 nM)。在分离的豚鼠心脏模型中，NPY能够增加灌注压（EC30 = 1.3 nM）。神经内注射NPY（300 pmol/动物）能够在大鼠中增加食物摄取量。

Sarafotoxin S6d (STX-b) 为从以色列沙蚺毒液中提取的多肽毒素。该物质能引起包括心肌缺血和高钾血症在内的多种 Electrocardiogram (ECG) 变化。此外，Sarafotoxin S6d 在大鼠主动脉中能够引发依赖于细胞外钙离子的强烈血管收缩作用，并在大鼠心房展现出正性肌力效果。该化合物被广泛用于心血管疾病的研究领域。

[Pro34]Neuropeptide Y, porcine是一种选择性NPY受体(Y1受体)激动剂，引起豚鼠腔静脉血管收缩。

Tetrahydrozoline (Tetryzoline) nitrate 是咪唑啉的衍生物。它是一种引起血管收缩的α-肾上腺素能 (α-adrenergic) 激动剂。Tetrahydrozoline 广泛用于鼻充血和结膜充血的研究。

Prostaglandin A1 (PGA1) was first isolated as a dehydration product of the PGE1 compounds found in human semen. 15-keto PGA1 is a metabolite of PGA1, produced by 15-hydroxy PG dehydrogenase. It can be produced from PGA1 in pig lung, trachea, aorta, and pulmonary artery tissue preparations. 15-keto PGA1, given at a concentration of 6 μM, causes vasoconstriction of rabbit lung that is comparable to that induced by angiotensin II.

Amastatin HCl is an inhibitor of aminopeptidase. It also induces vasoconstriction.

Auriculin A是一种合成ANF，它对血液动力学具有显著效应。该化合物可阻断犬的肾血管收缩，并在兔子的后肢灌注压、心率及动脉血压的全身调节中发挥作用。

[Ala1,3,11,15]-Endothelin (53-63) (TFA) 是一种ETB 激动剂。[Ala1,3,11,15]-Endothelin (53-63) (TFA) 对 ETB 具有选择性，IC50值范围为 0.33 nM 至 0.61 nM。[Ala1,3,11,15]-Endothelin (53-63) (TFA) 可用于血管收缩的研究。

Neuromedin U (NMU) is a neuropeptide first demonstrated to drive smooth muscle contraction.1Translated as a 174 amino acid propeptide, NMU is cleaved to different lengths in different animals. It has diverse receptor-mediated rolesin vivo, as it regulates feeding, vasoconstriction, nociception, and bone remodeling and contributes to obesity, cancer and septic shock.2,2NMU-25 is the active form of NMU in humans. It binds with high affinity to receptors on human left ventricle and coronary artery (KDs = 0.26 and 0.11 nM, respectively), eliciting endothelium-independent vasoconstriction.3NMU-25 also suppresses glucose-stimulated insulin secretion in human islets, and this effect is lost in NMU R165W mutants, resulting in early-onset obesity.4 1.Mitchell, J.D., Maguire, J.J., and Davenport, A.P.Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin SBritish Journal of Pharmacology15887-103(2009) 2.Greenwood, H.C., Bloom, S.R., and Murphy, K.G.Peptides and their potential role in the treatment of diabetes and obesityRev.Diabet.Stud.8(3)355-368(2011) 3.Mitchell, J.D., Maguire, J.J., Kuc, R.E., et al.Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular systemCardiovascular Research81353-361(2009) 4.Alfa, R.W., Park, S., Skelly, K.R., et al.Suppression of insulin production and secretion by a decretin hormoneCell Metabolism21(2)323-333(2015)

PD 142893 is a functional endothelin-stimulated vasoconstriction antagonist.

BQ-3020 (TFA) is a selective ETB receptor agonist that inhibits [125I] et-1 binding to the ETB receptor in the cerebellum with a 0.2nm IC50, causing vasoconstriction.

Neuropeptide Y (NPY) is a 36-amino acid neuropeptide that exerts its activity via G-protein-coupled receptors. NPY is widely distributed in the peripheral and central nervous systems. It modulates a variety of physiological processes, e.g. the central reg

Uridine-5'-O-(3-thiotriphosphate) (UTP-γ-S) 是UTP的一种抗水解衍生物，是嘌呤P2Y2受体的激动剂。在表达人类P2Y2受体的1321N1星形胶质瘤细胞中，其可诱导肌醇磷酸盐的形成（EC50 = 240 nM），并且在来自囊性纤维化患者的原代鼻上皮细胞中以浓度依赖的方式诱导氯离子分泌。UTP-γ-S在分离的人类冠状动脉中诱导血管收缩（EC50 = 25.1 µM）。

Clazosentan disodium (Ro 61-1790) 作为一种选择性内皮素 A 受体 (ETAreceptor) 拮抗剂，能够抑制 ET-1 所引发的血管收缩。此外，该化合物还具有预防脑血管痉挛和血管痉挛相关性脑梗死的功能。

BQ-3020 (TFA) 是一种选择性的内皮素受体 B (ETBreceptor) 激动剂，抑制小脑 [125I]ET-1 与 ETB 受体结合，IC50值为 0.2 nM。BQ-3020 (TFA) 可导致血管收缩。

Rimegepant, also known as BMS-927711 and BHV-3000, is a potent, selective, competitive, and orally active calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraines. Rimegepant has shown in vivo efficacy without vasoconstriction effect. BMS-927711 is superior to placebo at several different doses (75 mg, 150 mg, and 300 mg) and has an excellent tolerability profile.

12(S)-HpETE is a monohydroperoxy polyunsaturated fatty acid (PUFA) produced by the action of platelet or leukocyte 12-lipoxygenase (12-LO) on arachidonic acid. It activates human blood leukocyte 5-LO, resulting in the synthesis of 5(S)-HETE, leukotriene B4 (LTB4), and 5(S),12(S)-DiHETE. Rat lung metabolizes 12(S)-HpETE to 8,11,12- and 10,11,12-trihydroxyeicostrienoic acids. 12(S)-HpETE is the mediator of many biological functions, including induction of c-fos and c-jun, activation of AP-1, and endothelium-dependent vasoconstriction. It mediates the inhibitory synaptic response to FMRF-amide in Aplysia sensory neurons and inhibits Ca2+ calmodulin-dependent protein kinase II from rat brain cortex.

Angiotensin I II (2-7) is a peptide that contains the amino acids 2-7 and is converted from Angiotensin I II peptide. Angiotensin is a peptide hormone that causes vasoconstriction and a subsequent increase in blood pressure. Angiotensin also stimulates th

TRV120027 is a β-arrestin-1-biased agonist of the angiotensin II receptor type 1. TRV120027 inhibits angiotensin II-mediated vasoconstriction and increases cardiomyocyte contractility.

Rizatriptan-d6 is intended for use as an internal standard for the quantification of rizatriptan by GC- or LC-MS. Rizatriptan is an agonist of the serotonin receptor subtypes 5-HT1B and 5-HT1D. It is selective for 5-HT1B and 5-HT1D receptors over 5-HT1A receptors. Rizatriptan induces vasoconstriction in isolated human middle meningeal arteries. In vivo, rizatriptan reduces head grooming, the number of oculotemporal strokes, eye blinking, and one-eye closures in a Cacna1a mutant transgenic mouse model of migraine. Formulations containing rizatriptan have been used in the treatment of migraine.

Thromboxane A2, as an unstable intermediate between the prostaglandin endoperoxides and thromboxane B2, is a potent inducer of platelet aggregation and causes vasoconstriction.